Director General of Drug Administration Expresses Satisfaction During Surprise Visit to EDCL.

BDnewsExpress: Wednesday (6 May), the Director General of the Directorate General of Drug Administration, Md. Alamgir Hossain, conducted a surprise inspection at Essential Drugs Company Limited (EDCL). During the visit, he observed the production operations, quality control systems, storage and distribution processes, and the overall factory environment.

During the inspection, he exchanged views with the concerned officials and emphasized the importance of producing safe and effective medicines while maintaining international standards. He also instructed the authorities to strictly follow Good Manufacturing Practices (GMP) in all production activities.

At the end of the visit, the Director General expressed satisfaction with the various activities of EDCL and praised the organization for its role in ensuring the supply of quality medicines for the people of the country.

He stated that the use of modern technology in the production process must be further increased. He also stressed the need for regular training programs to enhance workforce skills. In addition, he directed the authorities to take effective initiatives to increase production capacity in order to meet the growing domestic demand, while continuing to maintain international standards in pharmaceutical manufacturing.

During the inspection, the Managing Director and Chief Executive Officer of Essential Drugs Company Limited, Md. A. Samad Mridha, guided the visit efficiently and presented the company’s ongoing activities and future development plans. He informed that there are plans to construct a modern multi-storied pharmaceutical manufacturing facility equipped with advanced technology on land allocated by the Ministry of Health and Family Welfare adjacent to the Dhaka factory, following international standards.

Managing Director Md. A. Samad Mridha  further stated that initiatives have been taken to establish separate facilities at the Gopalganj factory for the production of anti-venom and various vaccines. There are also plans to conduct the final-stage production of Measles-Rubella, Rabies, and Dengue vaccines there.

In addition, plans have been made to expand production at the Bogura factory and establish a separate packaging facility at the Khulna factory. It is expected that the implementation of these projects will further strengthen the supply of quality medicines in line with the country’s growing demand.